Key terms

About DCPH

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest DCPH news

Apr 08 8:40am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH) and Shockwave Medical (SWAV) by TipRanks Feb 21 6:51am ET Barclays Keeps Their Sell Rating on Deciphera Pharmaceuticals (DCPH) by TipRanks Feb 07 8:40am ET Stifel Nicolaus Remains a Buy on Deciphera Pharmaceuticals (DCPH) by TipRanks Feb 07 8:31am ET Buy Rating Reaffirmed for Deciphera Pharmaceuticals on Strong Q4 Performance and Promising Drug Prospects by TipRanks Feb 07 6:20am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Feb 07 5:19am ET Deciphera Pharmaceuticals (DCPH) Gets a Sell from Barclays by TipRanks Feb 07 12:50am ET Analysts Are Bullish on Top Healthcare Stocks: Deciphera Pharmaceuticals (DCPH), ACADIA Pharmaceuticals (ACAD) by TipRanks Feb 06 12:45pm ET Deciphera Pharmaceuticals: Strong Buy Rating on Robust Financials and Promising Pipeline by TipRanks Feb 06 11:35am ET Deciphera Pharmaceuticals: Sustained Growth and Market Expansion Drive Buy Rating by TipRanks Feb 06 7:08am ET Deciphera sees NDA submission for Vimseltinib in 2Q24 by TipRanks Feb 06 7:08am ET Deciphera sees NDA submission for Vimseltinib in 2Q24 by TipRanks Feb 06 7:04am ET Deciphera reports Q4 EPS (54c), consensus (58c) by TipRanks Jan 22 2:23pm ET Piper Sandler Remains a Buy on Deciphera Pharmaceuticals (DCPH) by TipRanks Jan 18 11:23am ET Deciphera presents long-term follow-up results from INTRIGUE Phase 3 trial by TipRanks Jan 12 6:37am ET Deciphera, GENESIS Pharma enter distribution agreement for RIPRETINIB by TipRanks Jan 11 1:33am ET Deciphera Pharmaceuticals: A Strong Buy on Impressive Qinlock Sales and Promising Vimseltinib Prospects by TipRanks

No recent press releases are available for DCPH

DCPH Financials

1-year income & revenue

Key terms

DCPH Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

DCPH Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming